Novus Biologicals Announces New Slitrk1 Antibody made using SDIX's Genomic Antibody Technologyâ„¢

Novus Biologicals announced today a new Slitrk1 antibody (catalog number NBP1-49541) for the study of Tourette syndrome and Trichotillomania.  This Slitrk-1 antibody was made using Genomic Antibody TechnologyTM (GATTM), a proprietary technology of SDIX.

Novus' new anti-Slitrk1 is an affinity purified rabbit polyclonal antibody that cross-reacts with human and mouse.  The Novus lab team has positively validated this Slitrk1 antibody for use in Western blot and immunohistochemistry.  By Western blot analysis on human and mouse brain lysates, a clear band at approximately 95 kDa was achieved. 

Slitrk1 is a protein thought to be involved in neurite outgrowth. Mutations in the Slitrk1 gene may be associated with Gilles de la Tourette syndrome (GTS) and Trichotillomania (TTM). GTS is a neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities. TTM is a neuropsychiatric disorder characterized by chronic, repetitive, or compulsive hair pulling resulting in noticeable hair loss. Often, GTS and TTM are overlapping psychological disorders.

GAT uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to that region of the protein in its naturally folded form. The ability of any antibody to recognize a protein’s naturally folded state has the potential to expand an antibody’s utility to high-value applications like sandwich immunoassay, ChIP, and flow cytometry.  Learn more about GAT by reading the GAT FAQ or by downloading the GAT White Paper.

About Novus Biologicals (

Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science.  Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community.  The Novus Guarantee + Innovator’s Rewardâ„¢ Policy 100% guarantees all of Novus' products to work in the species and applications listed on the datasheet.  Mainsail Partners, a San Francisco based private equity firm, has been an equity investor in Novus Biologicals since 2008. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.

About SDIX (

SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the pharmaceutical, biotechnology, diagnostics, and food safety markets. For 20 years, SDIX has developed antibodies which advance its customers’ immuno-based work – reducing time, labor, and costs while increasing accuracy and reliability of results.

SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development, and production.  In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide tools for rapid diagnosis.  


Release Date: 
Monday, January 24, 2011 - 07:00